Bristol-Myers Squibb Co at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 07:00PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD

Great. Good afternoon, everybody. I'm Terence Flynn, the biopharma analyst at Goldman Sachs, and we're very pleased to welcome Bristol-Myers Squibb today to our virtual conference.

Joining us from the company is Nadim Ahmed, who is Executive Vice President and President of Hematology; Chris Boerner, who's Executive Vice President and Head of Commercial -- Chief Commercial Officer. Looking forward to hosting you both today. Thank you for taking time out of your day to join us.

Questions and Answers:

Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD

Maybe just to get started, and again, maybe, Chris, this one would be for you. And, then, Nadim, you could add on anything here. We're obviously into June, and some states are starting to reopen now. And just wanted to check in on the operating environment and how that's tracking relative to the expectations that you outlined on your first quarter call, where you said you saw more -- a return to a more stable
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot